S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
Log in
ASX:GSS

Genetic Signatures Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Genetic Signatures (ASX:GSS) Vs. BUX, IME, BD1, CRL, CTE, and DVL

Should you be buying GSS stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to Genetic Signatures, including (BUX) (BUX), 12144 (IME), BARD1 Life Sciences (BD1), Charles River Laboratories International (CRL), Cryosite (CTE), and dorsaVi (DVL).

Genetic Signatures (ASX:GSS) and (BUX) (CNSX:BUX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Genetic Signatures and (BUX), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genetic Signatures0000N/A
(BUX)0000N/A

Profitability

This table compares Genetic Signatures and (BUX)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genetic SignaturesN/AN/AN/A
(BUX)N/AN/AN/A

Earnings & Valuation

This table compares Genetic Signatures and (BUX)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genetic Signatures$29.13 million0.00$4.71 millionA$0.03N/A
(BUX)N/AN/AN/AN/AN/A

Genetic Signatures has higher revenue and earnings than (BUX).

Summary

Genetic Signatures beats (BUX) on 1 of the 1 factors compared between the two stocks.

Genetic Signatures (ASX:GSS) and 12144 (CNSX:IME) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Genetic Signatures and 12144, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genetic Signatures0000N/A
121440000N/A

Profitability

This table compares Genetic Signatures and 12144's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genetic SignaturesN/AN/AN/A
12144N/AN/AN/A

Earnings & Valuation

This table compares Genetic Signatures and 12144's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genetic Signatures$29.13 million0.00C$4.71 millionA$0.03N/A
12144N/AN/AN/AN/AN/A

Genetic Signatures has higher revenue and earnings than 12144.

Summary

Genetic Signatures beats 12144 on 1 of the 1 factors compared between the two stocks.

Genetic Signatures (ASX:GSS) and BARD1 Life Sciences (ASX:BD1) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Genetic Signatures and BARD1 Life Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genetic Signatures0000N/A
BARD1 Life Sciences0000N/A

Profitability

This table compares Genetic Signatures and BARD1 Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genetic SignaturesN/AN/AN/A
BARD1 Life SciencesN/AN/AN/A

Earnings & Valuation

This table compares Genetic Signatures and BARD1 Life Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genetic Signatures$29.13 million0.00$4.71 millionA$0.03N/A
BARD1 Life Sciences$464,101.000.00$-5,746,881.60A($0.07)N/A

Genetic Signatures has higher revenue and earnings than BARD1 Life Sciences.

Summary

Genetic Signatures beats BARD1 Life Sciences on 3 of the 3 factors compared between the two stocks.

Genetic Signatures (ASX:GSS) and Charles River Laboratories International (CNSX:CRL) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Profitability

This table compares Genetic Signatures and Charles River Laboratories International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genetic SignaturesN/AN/AN/A
Charles River Laboratories InternationalN/AN/AN/A

Valuation and Earnings

This table compares Genetic Signatures and Charles River Laboratories International's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genetic Signatures$29.13 million0.00$4.71 millionA$0.03N/A
Charles River Laboratories InternationalN/AN/AN/AN/AN/A

Genetic Signatures has higher revenue and earnings than Charles River Laboratories International.

Analyst Recommendations

This is a summary of current recommendations and price targets for Genetic Signatures and Charles River Laboratories International, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genetic Signatures0000N/A
Charles River Laboratories International0000N/A

Summary

Genetic Signatures beats Charles River Laboratories International on 1 of the 1 factors compared between the two stocks.

Genetic Signatures (ASX:GSS) and Cryosite (ASX:CTE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Profitability

This table compares Genetic Signatures and Cryosite's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genetic SignaturesN/AN/AN/A
CryositeN/AN/AN/A

Valuation and Earnings

This table compares Genetic Signatures and Cryosite's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genetic Signatures$29.13 million0.00$4.71 millionA$0.03N/A
Cryosite$8.97 million0.00$1.41 millionA$0.03N/A

Genetic Signatures has higher revenue and earnings than Cryosite.

Analyst Recommendations

This is a summary of current recommendations and price targets for Genetic Signatures and Cryosite, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genetic Signatures0000N/A
Cryosite0000N/A

Summary

Genetic Signatures beats Cryosite on 3 of the 3 factors compared between the two stocks.

dorsaVi (ASX:DVL) and Genetic Signatures (ASX:GSS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Analyst Ratings

This is a summary of current ratings and target prices for dorsaVi and Genetic Signatures, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
dorsaVi0000N/A
Genetic Signatures0000N/A

Profitability

This table compares dorsaVi and Genetic Signatures' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
dorsaViN/AN/AN/A
Genetic SignaturesN/AN/AN/A

Valuation & Earnings

This table compares dorsaVi and Genetic Signatures' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
dorsaVi$2.02 million0.00$-12,244,714.72A($0.04)N/A
Genetic Signatures$29.13 million0.00$4.71 millionA$0.03N/A

Genetic Signatures has higher revenue and earnings than dorsaVi.

Summary

Genetic Signatures beats dorsaVi on 3 of the 3 factors compared between the two stocks.


Genetic Signatures Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BUX
(BUX)
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
IME
12144
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Down
BD1
BARD1 Life Sciences
0.8N/AN/A$0.00$464,101.000.00High Trading Volume
Gap Up
CRL
Charles River Laboratories International
0.5N/AN/A$0.00N/A0.00Gap Up
CTE
Cryosite
0.6N/AN/A$0.00$8.97 million0.00High Trading Volume
Gap Up
DVL
dorsaVi
0.5N/AN/A$0.00$2.02 million0.00High Trading Volume
Gap Up
EPGNY
Epigenomics
0.6$14.15flat$0.00N/A0.00
ETAH
Eternity Healthcare
0.6$0.00flat$0.00N/A0.00Gap Up
GTG
Genetic Technologies
0.0N/AN/A$0.00$9,864.000.00High Trading Volume
IBX
Imagion Biosystems
0.6N/AN/A$0.00$2.70 million0.00High Trading Volume
Gap Up
IDX
Integral Diagnostics
0.8N/AN/A$0.00$275.57 million0.00Dividend Announcement
High Trading Volume
Gap Up
LSH
Lifespot Health
0.5N/AN/A$0.00$43,975.000.00High Trading Volume
Gap Up
MEDD
Medical Imaging
0.4$0.01flat$0.00N/A0.00Decrease in Short Interest
Gap Down
OSL
OncoSil Medical
0.5N/AN/A$0.00$2.76 million0.00High Trading Volume
Gap Up
PRLX
Parallax Health Sciences
0.5$0.01flat$0.00N/A0.00High Trading Volume
RHY
Rhythm Biosciences
0.0N/AN/A$0.00$100,000.000.00High Trading Volume
Sartorius Aktiengesellschaft logo
SRT3
Sartorius Aktiengesellschaft
0.6$425.40flat$0.00N/A0.00High Trading Volume
Siemens Healthineers logo
SMMNY
Siemens Healthineers
0.4$27.81flat$0.00N/A0.00Analyst Report
Decrease in Short Interest
SIL
Smiles Inclusive
0.4N/AN/A$0.00$36.48 million0.00High Trading Volume
Gap Up
VHT
Volpara Health Technologies Limited (VHT.AX)
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
OBJ
Wellfully Limited (OBJ.AX)
0.0N/AN/A$0.00$1.48 million0.00High Trading Volume
WUXIF
WuXi AppTec
1.0$14.80flat$0.00N/A0.00
This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.